Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Rubius Therapeutics, Inc.
Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Number of employees : 204 people.
Managers
Name Title Age Since
Pablo J. Cagnoni, Dr. President, Chief Executive Officer & Director 57 2019
Jose Carmona Treasurer, Chief Financial & Accounting Officer 48 2020
Spencer Fisk Senior Vice President-Technical Operations - -
Christina Coughlin, Dr. Chief Medical Officer 50 2020
Laurence Turka, Dr. Chief Scientific Officer 62 2020
Dannielle Appelhans Chief Operating Officer 37 2021
Noubar Afeyan Independent Director 58 2013
Michael A. Rosenblatt, Dr. Independent Director 72 2014
Francis M. Cuss, Dr. Independent Director 67 2018
Catherine Angell Sohn, Dr. Independent Director 67 2018
Members of the board
Name Title Age Since
David R. Epstein Executive Chairman 59 2017
Noubar Afeyan Independent Director 58 2013
Michael A. Rosenblatt, Dr. Independent Director 72 2014
Francis M. Cuss, Dr. Independent Director 67 2018
Catherine Angell Sohn, Dr. Independent Director 67 2018
Jonathan Symonds Independent Non-Executive Director 61 2018
Pablo J. Cagnoni, Dr. President, Chief Executive Officer & Director 57 2019
Natalie C. Holles Independent Director 47 2019
Anne Prener, Dr. Independent Director 62 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 89,773,882 83,782,724 93.3% 0 0.0% 93.3%
Shareholders
NameEquities%
Flagship Pioneering 38,506,526 42.9%
Fidelity Management & Research Co. LLC 13,527,493 15.1%
David R. Epstein 4,870,012 5.42%
Baillie Gifford & Co. 4,693,832 5.23%
Invus Public Equities Advisors LLC 4,633,791 5.16%
The Vanguard Group, Inc. 3,125,566 3.48%
ARCH Venture Partners LLC 2,618,351 2.92%
SSgA Funds Management, Inc. 2,440,295 2.72%
JPMorgan Investment Management, Inc. 1,634,116 1.82%
Victory Capital Management, Inc. (Investment Management) 1,572,187 1.75%
Company contact information
Rubius Therapeutics, Inc.
399 Binney Street
Suite 300
Cambridge, MA 02139

Phone : +1.617.679.9600
Web : http://www.rubiustx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Rubius Therapeutics, Inc.
Sector Bio Therapeutic Drugs